LIVER-R is a study about real-world data for patients with hepatobiliary cancer (cancer in the liver or bile ducts). It looks at how well patients do with a medicine called durvalumab as part of their usual care. In this study, doctors will collect information from about 2500 patients from 22 different countries.

Patients who can join must be at least 18 years old and already getting durvalumab for this type of cancer. They can’t be in any other trial or have had other special treatments like a liver transplant. The study will last for up to 3 years for some patients, and 2 years for others, depending on their condition.

• The study is observational, which means it just looks at what happens without changing any treatments.
• Doctors will collect information from medical records and regular visits every 6 months.
• There won’t be extra tests or treatments, and no new medicines are being tested.